Assenagon Asset Management
RNAM

Assenagon Asset Management’s Avidity Biosciences RNAM Stock Holding History

Assenagon Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,923
Closed -$2M – 1244
2025
Q3 		$2M Buy
45,923
+28,055
+157% +$1.13M ﹤0.01% 817
2025
Q2 		$507K Sell
17,868
-189,504
-91% -$5.65M ﹤0.01% 1030
2025
Q1 		$6.12M Buy
207,372
+166,813
+411% +$5.2M 0.01% 509
2024
Q4 		$1.18M Buy
+40,559
New +$1.69M ﹤0.01% 1072
2024
Q3 		– Sell
-48,969
Closed -$2M – 1462
2024
Q2 		$2M Buy
+48,969
New +$1.41M ﹤0.01% 899

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management's RNAM Position: Q4 2025 in Review

Assenagon Asset Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 45,923 shares — an estimated $2M sold.

Assenagon Asset Management first reported a position in RNAM in Q2 2024 and held it in 5 quarters. The position peaked at $6.12M in Q1 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Assenagon Asset Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 45,923 Avidity Biosciences shares in Q4 2025, an estimated $2M.
  • Assenagon Asset Management first reported a position in Avidity Biosciences in Q2 2024 and held it in 5 quarters.
  • Assenagon Asset Management's Avidity Biosciences position peaked at $6.12M in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Assenagon Asset Management's 13F filing for Q4 2025, filed 9 Jan 2026.